Additionally, DSBs can stimulate the cGAS–STING pathway, inducing PD‐L1 expression and creating an immunosuppressive microenvironment,53 indicating that the combination of PARPi and PD‐L1 inhibitor can be a potential treatment modality for SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.